[go: up one dir, main page]

WO2006062980A3 - Stable non-crystalline formulation comprising tiagabine - Google Patents

Stable non-crystalline formulation comprising tiagabine Download PDF

Info

Publication number
WO2006062980A3
WO2006062980A3 PCT/US2005/044133 US2005044133W WO2006062980A3 WO 2006062980 A3 WO2006062980 A3 WO 2006062980A3 US 2005044133 W US2005044133 W US 2005044133W WO 2006062980 A3 WO2006062980 A3 WO 2006062980A3
Authority
WO
WIPO (PCT)
Prior art keywords
tiagabine
stable non
crystalline formulation
formulations
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/044133
Other languages
French (fr)
Other versions
WO2006062980A2 (en
Inventor
Caroline German
Christian Barnett
Jiang Zhang
Stephanie Gong
David Lechuga
Sarma Duddu
Andreas Kordikowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of WO2006062980A2 publication Critical patent/WO2006062980A2/en
Publication of WO2006062980A3 publication Critical patent/WO2006062980A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On or more embodiments of the invention provide various novel formulations comprising tiagabine that are non-crystalline, more stable, and/or otherwise improvements over known tiagabine formulations. The tiagabine-containing formulations may be administered to a user to treat epilepsy.
PCT/US2005/044133 2004-12-07 2005-12-07 Stable non-crystalline formulation comprising tiagabine Ceased WO2006062980A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63399104P 2004-12-07 2004-12-07
US63395304P 2004-12-07 2004-12-07
US60/633,953 2004-12-07
US60/633,991 2004-12-07

Publications (2)

Publication Number Publication Date
WO2006062980A2 WO2006062980A2 (en) 2006-06-15
WO2006062980A3 true WO2006062980A3 (en) 2007-02-08

Family

ID=36096207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044133 Ceased WO2006062980A2 (en) 2004-12-07 2005-12-07 Stable non-crystalline formulation comprising tiagabine

Country Status (1)

Country Link
WO (1) WO2006062980A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051435A1 (en) * 2006-08-18 2008-02-28 Cephalon, Inc. Crystalline and amorphous forms of tiagabine
US20080064727A1 (en) * 2006-08-18 2008-03-13 Cephalon, Inc. Crystalline forms of tiagabine hydrochloride
EP2155166A2 (en) * 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
WO2013167986A2 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of epilepsy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988863A2 (en) * 1998-09-22 2000-03-29 F. Hoffmann-La Roche Ag Stable complexes of poorly soluble compounds
US20030042166A1 (en) * 2001-03-16 2003-03-06 Waterman Kenneth C. Pharmaceutical kit for oxygen-sensitive drugs
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US20040178529A1 (en) * 2001-07-02 2004-09-16 Ernesto Reverchon Process for the production of micro and/or nano particles
WO2005092886A1 (en) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous form of tiagabine
WO2005122698A2 (en) * 2003-12-24 2005-12-29 Sun Pharmaceutical Industries Limited Novel stable polymorphic forms of tiagabine hydrochloride

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988863A2 (en) * 1998-09-22 2000-03-29 F. Hoffmann-La Roche Ag Stable complexes of poorly soluble compounds
US20030042166A1 (en) * 2001-03-16 2003-03-06 Waterman Kenneth C. Pharmaceutical kit for oxygen-sensitive drugs
US20040178529A1 (en) * 2001-07-02 2004-09-16 Ernesto Reverchon Process for the production of micro and/or nano particles
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
WO2005122698A2 (en) * 2003-12-24 2005-12-29 Sun Pharmaceutical Industries Limited Novel stable polymorphic forms of tiagabine hydrochloride
WO2005092886A1 (en) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous form of tiagabine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUNG J ET AL: "Particle design using supercritical fluids: Literature and patent survey", JOURNAL OF SUPERCRITICAL FLUIDS, PRA PRESS, US, vol. 20, no. 3, August 2001 (2001-08-01), pages 179 - 219, XP004735157, ISSN: 0896-8446 *

Also Published As

Publication number Publication date
WO2006062980A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
WO2006050477A3 (en) Anti-microbial compositions and methods of making and using the same
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
IL209494A (en) Insulin-oligomer monoconjugates, formulations and uses thereof
WO2004108133A3 (en) Modulators of vr1 receptor
WO2004021968A3 (en) Solution for ungual application
WO2008009379A3 (en) Active ingredient combinations having insecticide and acaricide properties
WO2006037810A3 (en) Protracted glp-1 compounds
TW200637522A (en) Skin treatment articles and methods
WO2004006858A3 (en) Compounds, compositions, and methods employing same
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
WO2005007142A3 (en) Liquid compositions comprising formoterol
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
WO2005089728A3 (en) Means for transdermal administration of nicotine
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2008098180A3 (en) Complementary personal lubrificant compositions and delivery system
IL192206A0 (en) Topical mecamylamine formulations for ocular administration and uses thereof
WO2005044200A3 (en) Methods and compositions for treating mcp-1 related pathologies
IL181300A (en) Photosensitizer formulations and uses thereof
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
WO2005070183A3 (en) Ice cream and ice cream formulations containing maltitol
WO2006076097A3 (en) Stable non-crystalline formulation comprising losartan
AU2003219046A1 (en) Cationic polymers and the use thereof in cosmetic formulations
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
WO2004037168A3 (en) Treatment of pancreatitis with amylin
WO2006062980A3 (en) Stable non-crystalline formulation comprising tiagabine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05853142

Country of ref document: EP

Kind code of ref document: A2